MiMedx Group (MDXG) Expected to Announce Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) will likely be announcing its Q1 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $86.32 million for the quarter.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Stock Performance

Shares of NASDAQ:MDXG opened at $6.83 on Tuesday. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14. The stock has a market capitalization of $1.01 billion, a P/E ratio of 12.42 and a beta of 1.74. The firm has a fifty day simple moving average of $7.51 and a two-hundred day simple moving average of $8.08. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MDXG shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 16th.

Insider Activity at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 81,446 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares of the company’s stock, valued at approximately $3,859,237.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares in the company, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 144,018 shares of company stock worth $1,130,312. Insiders own 1.30% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.